Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.

October 23, 2026

Vol.52 No.39

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Bristol Myers Squibb on Sept. 8 announced positive phase II results from the registrational QUINTESSENTIAL trial (NCT06297226) of arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM).

September 18, 2026

Vol.52 No.34

Drugs & Targets

FDA grants accelerated approval to iberdomide combination for MM

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

September 11, 2026

Vol.52 No.33

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

YOU MAY BE INTERESTED IN

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

FDA grants accelerated approval to iberdomide combination for MM

Renew today!

Subscriber content

Never miss an issue!

Login